Embecta Corp. (EMBC) vs Kyverna Therapeutics, Inc. (KYTX)

A side-by-side comparison of Embecta Corp. and Kyverna Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Embecta Corp. logo
EMBC
Embecta Corp.
$359M
$6.06HealthcareDelayed quote: Oct 6, 2026, 12:40 PM EDT
Kyverna Therapeutics, Inc. logo
KYTX
Kyverna Therapeutics, Inc.
$384M
$6.31HealthcareDelayed quote: Oct 6, 2026, 12:40 PM EDT

Total return — EMBC vs KYTX

growth of $100 · dividends reinvested · last 3y
EMBC -62.5% (-27.9%/yr)KYTX -78.9% (-40.5%/yr)EMBC compounded faster over this window
050100Start $10020252026$37$21
EMBC KYTX

EMBC vs KYTX: by the numbers

  • •KYTX is the larger company ($384M vs $359M market cap).
  • •EMBC is profitable (8.59% net margin) while KYTX runs a net loss (0.00%).
  • •EMBC pays a dividend (5.44% yield), while KYTX has no payments in the available dividend history.

Metrics side by side

Valuation

MetricEMBCKYTX
P/E ratio4.09N/A
Forward P/E3.44N/A
P/S ratio0.35N/A
P/B ratioN/A2.32
EV / EBITDA5.40N/A
FCF yield45.81%N/A

Profitability

MetricEMBCKYTX
Gross margin59.89%0.00%
Operating margin24.85%0.00%
Net margin8.59%0.00%
ROEN/A-92.20%
ROIC17.99%-80.67%

Dividends

MetricEMBCKYTX
Dividend yield5.44%N/A
Payout ratio21.62%N/A

Growth (annualized)

MetricEMBCKYTX
Revenue CAGR (5Y)-0.09%N/A
EPS CAGR (5Y)-26.22%N/A
FCF CAGR (5Y)-16.77%N/A

Frequently asked

Does EMBC or KYTX pay a bigger dividend?
EMBC pays a dividend (5.44% yield), while KYTX has no payments in the available dividend history.
Is EMBC or KYTX more profitable?
EMBC runs the higher net margin — EMBC at 8.59% versus KYTX at 0.00%.

Go deeper

Full EMBC analysisFull KYTX analysisInteractive comparison tool

Dig into the metrics

Embecta P/E ratioEmbecta dividend yieldEmbecta ROEKyverna Therapeutics ROEEmbecta operating marginKyverna Therapeutics operating marginEmbecta revenue growthKyverna Therapeutics revenue growthEmbecta free cash flowKyverna Therapeutics free cash flow

Embecta & Kyverna Therapeutics appear in these rankings

Highest Dividend Yield StocksHighest FCF Yield StocksLowest P/E Ratio Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.